Skip to content

Comparing the Quality of Life Between LADG and TLDG for Gastric Cancer_KLASS07 (CKLASS01)).

A Multicenter Randomized Controlled Trial Comparing the Quality of Life Between Laparoscopy-assisted Distal Gastrectomy and Totally Laparoscopic Distal Gastrectomy for Gastric cancer_KLASS 07 (CKLASS01)(Korea-China Collaborated Study)

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03393182
Enrollment
443
Registered
2018-01-08
Start date
2018-03-01
Completion date
2022-02-18
Last updated
2022-04-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric Cancer, Quality of Life, Surgery, Surgical Complication

Brief summary

The present randomized study is designed to compare the quality of life between the patients undergoing laparoscopy-assisted and totally laparoscopic distal gastrectomy for gastric cancer, and therefore to evaluate the superiority of totally laparoscopic distal gastrectomy to laparoscopy-assisted distal gastrectomy.

Detailed description

The primary endpoint of this trial is the early postoperative morbidity, that is defined as complications that occur within 30 days after surgery. Early postoperative morbidity is classified as follows: (1) wound morbidity (2) surgical site morbidity: anastomosis bleeding or leakage, duodenal stump leakage, postoperative bleeding, afferent loop or efferent loop obstruction, etc.; (3) lung morbidity: atelectasis, pleural effusion, empyema, pneumothorax, etc.; (4) intestinal obstruction morbidity (5) urinary tract morbidity (6) intra-abadominal abscess (7) postoperative pancreatitis (8) pancreatic fistula (9) intestinal fistula 10) others: lymphorrhea, diarrhea, etc. The secondary end point is the questionnaire score regarding QOL. This is assessed by the Korean versions of the EORTC QLQ-C30 (version 3.0) and STO22 questionnaires.

Interventions

PROCEDURETLDG arm

After lymphadenectomy, gastrectomy and reconstruction procedure are performed intracorporeally without mini-laparotomy(TLDG)

PROCEDURELADG arm

After lymphadenectomy, gastrectomy and reconstruction procedure are performed extracorporeally through mini-laparotomy(LADG)

Sponsors

Shanghai Medical College of Fudan University
CollaboratorUNKNOWN
Korea University Anam Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Intervention model description

Prospective, randomized, multi-center trial that comparing surgical complications and Quality of Life between Totally laparoscopic distal gastrectomy and Laparoscopy-assisted distal gastrectomy in Korea.

Eligibility

Sex/Gender
ALL
Age
20 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Histologic proven gastric adenocarcinoma (by preoperative gastrofiberscopy) * Age between 20 and 80 years old * Eastern Cooperative Oncology Group performance statu of 0 or 1 * Clinical stage IA (T1N0M0) or IB (T1N1M0 / T2N0M0) according to the 7th edition of the American Joint Committee on Cancer system10 (Clinical stage was determined based on the finding of gastrofiberscopy and abdominal computed tomography) * Scheduled for laparoscopic distal gastrectomy with D1+ or D2 lymphadenectomy, and possible for R0 surgery by this procedures (Lymphadenectomy is performed on the basis of the criteria of the Japanese Gastric Cancer Treatment Guidelines 2010 (ver.3).) * Patients who gave a consent and signed the formal paper permitted by Institutional Review Board (IRB) after hearing a full description of the study (purpose and contents) prior to the participation

Exclusion criteria

* Patients who received stomach surgery (i.e. gastrectomy or gastrojejunostomy) in the past * Patients with intraabdominal adhesion due to previous intraperitoneal surgery * Patients who recently diagnosed with gastric cancer and received either anticancer treatment or radiation therapy * Patients who requires combined organ resection due to aggression of gastric cancer or other diseases * Patients who received surgeries due to primary cancer of other organs, or had anticancer treatment or radiation therapy in the last five years (patients whose skin basal cell carcinoma and insitu cervical cancer are completely cured are exceptions). * Vulnerable people who can't communicate or are pregnant (or planning to be pregnant) * Patients who are currently participating or participated in other clinical trials in the last six months.

Design outcomes

Primary

MeasureTime frameDescription
Postoperative 30-day morbidity ratePostoperative 30-dayCheck the morbidity rate :Wound, seroma, hematoma, wound infection, wound dehiscence, wound evisceration, Fluid collection/Abscess, Intraabdominal bleeding, Intraluminal bleeding, Postoperative ileus, Anastomosis stenosis, Anastomosis leakage, Pancreatitis or pancreatic fistula, Complication(Pulmonary, Urinary, Renal, Hepatic, Cardiac, Endocrine) etc.

Secondary

MeasureTime frameDescription
QOL measurement : EORTC QLQ-C30/STO22screening(pre op) / Postoperative 30-day,3-month,6-month,12-monthEORTC QLQ-C30/STO22

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 21, 2026